Inter- and intrasubject variability of the inflammatory response to segmental endotoxin challenge in healthy volunteers

Pulmonary Pharmacology and Therapeutics

Volumn 35, Issue , 2015, Pages 50-59

  Holz, O ^a,b   Tan, L ^c   Schaumann, F ^a   Muller M ^a   Scholl, D ^c   Hidi, R ^c   McLeod, A ^c   Krug, N ^a,b   Hohlfeld, J M ^a,b  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b Member of the German Center for Lung Research   (Germany)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Airway inflammation; Challenge model; Clinical drug development; Lipopolysaccharide (LPS); Pharmacodynamic model; Reproducibility

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; ENDOTOXIN; LIPOPOLYSACCHARIDE;

ADULT; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CELL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; COUGHING; CYTOKINE RESPONSE; DIARRHEA; EOSINOPHIL; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN EXPERIMENT; LUNG ALVEOLITIS; LYMPHOCYTE; MACROPHAGE; MALE; MONOCYTE; NAUSEA; NEUTROPHIL; NORMAL HUMAN; OUTCOME VARIABLE; PLASMA; PLEURAL PAIN; PRIORITY JOURNAL; REPRODUCIBILITY; RESPIRATORY TRACT INFLAMMATION; SAFETY; SAMPLE SIZE; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; LUNG FUNCTION TEST; PATHOLOGY; PNEUMONIA;

ADULT; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHEMOKINES; COHORT STUDIES; CYTOKINES; ENDOTOXINS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; NEUTROPHILS; PNEUMONIA; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS;

EID: 84959302159     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.10.011     Document Type: Article

References (26)

1. Anonymous From the Global Strategy for the Diagnosis, Management and Prevention of COPD 2010, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. http://www.goldcopd.com/.
2. Sapey E., Bayley D., Ahmad A., Newbold P., Snell N., Stockley R.A. Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability. Thorax 2008, 63:493-499.
3. Holz O., Tal-Singer R., Kanniess F., Simpson K.J., Gibson A., Vessey R.S., Janicki S., Magnussen H., Jorres R.A., Richter K. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J. Clin. Pharmacol 2005, 45:498-503.
4. Michel O., Nagy A.M., Schroeven M., Duchateau J., Neve J., Fondu P., Sergysels R. Dose-response relationship to inhaled endotoxin in normal subjects. Am. J. Respir. Crit. Care Med 1997, 156:1157-1164.
5. Hernandez M.L., Harris B., Lay J.C., Bromberg P.A., Diaz-Sanchez D., Devlin R.B., Kleeberger S.R., Alexis N.E., Peden D.B. Comparative airway inflammatory response of normal volunteers to ozone and lipopolysaccharide challenge. Inhal. Toxicol 2010, 22:648-656.
6. O'Grady N.P., Preas H.L., Pugin J., Fiuza C., Tropea M., Reda D., Banks S.M., Suffredini A.F. Local inflammatory responses following bronchial endotoxin instillation in humans. Am. J. Respir. Crit. Care Med 2001, 163:1591-1598.
7. Holz O., Khalilieh S., Ludwig-Sengpiel A., Watz H., Stryszak P., Soni P., Tsai M., Sadeh J., Magnussen H. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur. Respir. J. 2010, 35:564-570. 09031936.00048509. 10.1183/09031936.00048509.
8. Michel O., Dentener M., Cataldo D., Cantinieaux B., Vertongen F., Delvaux C., Murdoch R.D. Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human. Pulm. Pharmacol. Ther 2007, 20(676-683). S1094-5539(06)00089-7. 10.1016/j.pupt.2006.08.002.
9. Hohlfeld J.M., Schoenfeld K., Lavae-Mokhtari M., Schaumann F., Mueller M., Bredenbroeker D., Krug N., Hermann R. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm. Pharmacol. Ther 2008, 21(616-623). S1094-5539(08)00017-5. 10.1016/j.pupt.2008.02.002.
10. Rylander R. Endotoxin in the environment-exposure and effects. J. Endotoxin Res 2002, 8:241-252. 10.1179/096805102125000452.
11. Hasday J.D., Bascom R., Costa J.J., Fitzgerald T., Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999, 115:829-835.
12. Michel O., Duchateau J., Plat G., Cantinieaux B., Hotimsky A., Gerain J., Sergysels R. Blood inflammatory response to inhaled endotoxin in normal subjects. Clin. Exp. Allergy 1995, 25:73-79.
13. Sandstrom T., Bjermer L., Rylander R. Lipopolysaccharide (LPS) inhalation in healthy subjects increases neutrophils, lymphocytes and fibronectin levels in bronchoalveolar lavage fluid. Eur. Respir. J. 1992, 5:992-996.
14. Kharitonov S.A., Sjobring U. Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib. Microbiol 2007, 14:83-100. 107056. 10.1159/0000107056.
15. Maris N.A., de Vos A.F., Dessing M.C., Spek C.A., Lutter R., Jansen H.M., van der Zee J.S., Bresser P., van der Poll T. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am. J. Respir. Crit. Care Med 2005, 172(878-884). 200503-451OC. 10.1164/rccm.200503-451OC.
16. Nick J.A., Coldren C.D., Geraci M.W., Poch K.R., Fouty B.W., O'Brien J., Gruber M., Zarini S., Murphy R.C., Kuhn K., Richter D., Kast K.R., Abraham E. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004, 104:3878-3885. 2004-06-2140. 10.1182/blood-2004-06-2140.
17. Aul R., Armstrong J., Duvoix A., Lomas D., Hayes B., Miller B.E., Jagger C., Singh D. Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. Br J Clin Pharmacol 2012, 10.1111/j.1365-2125.2012.04287.x.
18. Michel O., Duchateau J., Sergysels R. Effect of inhaled endotoxin on bronchial reactivity in asthmatic and normal subjects. J. Appl. Physiol. (1985) 1989, 66:1059-1064.
19. Alexis N.E., Lay J.C., Almond M., Peden D.B. Inhalation of low-dose endotoxin favors local T(H)2 response and primes airway phagocytes in vivo. J. Allergy Clin. Immunol 2004, 114:1325-1331. S0091674904023103. 10.1016/j.jaci.2004.09.002.
20. Janssen O., Schaumann F., Holz O., Lavae-Mokhtari B., Welker L., Winkler C., Biller H., Krug N., Hohlfeld J.M. Low-dose endotoxin inhalation in healthy volunteers-a challenge model for early clinical drug development. BMC Pulm. Med 2013, 13(19). 1471-2466-13-19. 10.1186/1471-2466-13-19.
21. Atochina-Vasserman E.N., Winkler C., Abramova H., Schaumann F., Krug N., Gow A.J., Beers M.F., Hohlfeld J.M. Segmental allergen challenge alters multimeric structure and function of surfactant protein D in humans. Am. J. Respir. Crit. Care Med 2011, 183(856-864). 201004-0654OC. 10.1164/rccm.201004-0654OC.
22. Mudway I.S., Kelly F.J. An investigation of inhaled ozone dose and the magnitude of airway inflammation in healthy adults. Am. J. Respir. Crit. Care Med 2004, 169:1089-1095. 200309-1325PP. 10.1164/rccm.200309-1325PP.
23. Greenaway S.D., Ward J., Tan E., Alölenby M.A., Hidi R., Bennetts M., Cadman J., O'Connor B.J. Low dose (15mcg) lipopolysaccharide (LPS) inhalation in healthy subjects - a model of airway inflammation. Am. J. Respir. Crit. Care Med 2006, A235.
24. Belda J., Leigh R., Parameswaran K., O'Byrne P.M., Sears M.R., Hargreave F.E. Induced sputum cell counts in healthy adults. Am. J. Respir. Crit. Care Med 2000, 161:475-478. 10.1164/ajrccm.161.2.9903097.
25. Spanevello A., Confalonieri M., Sulotto F., Romano F., Balzano G., Migliori G.B., Bianchi A., Michetti G. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am. J. Respir. Crit. Care Med 2000, 162:1172-1174. 10.1164/ajrccm.162.3.9908057.
26. Holz O., Jorres R.A., Timm P., Mucke M., Richter K., Koschyk S., Magnussen H. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. Am. J. Respir. Crit. Care Med 1999, 159:776-784.